ARTICLE | Strategy
Marriage of minds
Why Takeda put its epilepsy candidate in Ovid’s hands for global co-development
January 20, 2017 10:24 PM UTC
An unusual deal between Takeda Pharmaceutical Co. Ltd. and Ovid Therapeutics Inc. represents both a continuation of the biotech CEO’s long-time approach to portfolio building, and a new way of thinking about external innovation at the Japanese pharma.
The deal will see the partners co-develop Takeda’s TAK-935 globally for rare epileptic encephalopathies under a 50/50 cost- and profit-sharing arrangement, with Ovid taking the lead on clinical development...